Pharma Predictions for 2021
Catalent CEO John Chiminski to talks about the year ahead, offering projections for what 2021 holds in store for the biopharma industry.
From Candidate to Clinic: Strategies to Accelerate Your Molecule’s Development Path
The development of orally administered small molecules is more challenging as an many have poor aqueous solubility and bioavailability.
Strategies for De-risking Early-Phase Oral Small Molecule Drug Development
Summary: Characterize lead molecules and develop the best pathway to bring them to Phase I studies and beyond.
Partnering for Success: Strategies to Mitigate Common Pitfalls in Early Drug Development
Summary: Thousands of drug candidates are abandoned annually due to solubility and bioavailability issues, but advanced formulation technologies can profoundly impact how a drug compound…
Early Drug Development: Strategy and Solution
This webinar focuses on the key considerations for transitioning small molecules from preclinical through clinical development.
From Development to Commercialization: Overcoming Scale-Up Issues
Summary: Recorded at Manufacturing Chemist Live 2020, this presentation discusses some of the key issues to consider when planning for the scale-up of a small molecule development program.